Last week, Medtronic (NYSE:MDT) announced that one untested, yet promising therapy that it is developing had been accepted by a U.S. Food and Drug Administration pilot program meant to provide early feasibility testing of innovative medical devices. In fact, the Minnesota medical device maker’s stent graft totreat thoracic aortic aneurysmswas one of nine devices chosen by the FDA to be part of the Early Feasibility Medical Devices Clinical Studies program, the news release noted. What devices and what companies comprise the other eight?
